Literature DB >> 30527643

The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.

Michael Jonathan Kucharczyk1, Gwenaelle Gravis2, Tamim Niazi3.   

Abstract

The natural history and molecular biology of oligometastatic prostate cancer differentiate it from polymetastatic disease. Clinically, oligometastatic disease is also predictive and prognostic for different outcomes. Studies specific to this population are required to establish the benefits of intervention.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30527643     DOI： 10.1016/j.euf.2018.11.011

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  3 in total

1.  Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.

Authors:  Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu
Journal:  World J Urol       Date:  2022-10-02       Impact factor: 3.661

2.  Competitive Advantage of PSMA Theranostics in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Radiology       Date:  2021-03-30       Impact factor: 29.146

Review 3.  Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer.

Authors:  Giulia Marvaso; Stefania Volpe; Matteo Pepa; Mattia Zaffaroni; Giulia Corrao; Matteo Augugliaro; Franco Nolè; Ottavio De Cobelli; Barbara Alicja Jereczek-Fossa
Journal:  Cancer Manag Res       Date:  2022-01-06       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.